JP2025508702A5 - - Google Patents
Info
- Publication number
- JP2025508702A5 JP2025508702A5 JP2024547690A JP2024547690A JP2025508702A5 JP 2025508702 A5 JP2025508702 A5 JP 2025508702A5 JP 2024547690 A JP2024547690 A JP 2024547690A JP 2024547690 A JP2024547690 A JP 2024547690A JP 2025508702 A5 JP2025508702 A5 JP 2025508702A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- fluoro
- pyrrolidine
- amino
- fluorotetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310915P | 2022-02-16 | 2022-02-16 | |
| US63/310,915 | 2022-02-16 | ||
| PCT/US2023/062687 WO2023159086A1 (en) | 2022-02-16 | 2023-02-15 | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508702A JP2025508702A (ja) | 2025-04-10 |
| JP2025508702A5 true JP2025508702A5 (enExample) | 2026-02-25 |
Family
ID=85685573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547690A Pending JP2025508702A (ja) | 2022-02-16 | 2023-02-15 | キナゾリン化合物、及び変異ｋｒａｓタンパク質の阻害剤としてのその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250163064A1 (enExample) |
| EP (1) | EP4479401A1 (enExample) |
| JP (1) | JP2025508702A (enExample) |
| CN (1) | CN118974055A (enExample) |
| AU (1) | AU2023222076A1 (enExample) |
| CA (1) | CA3251001A1 (enExample) |
| MX (1) | MX2024010045A (enExample) |
| WO (1) | WO2023159086A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| JP2025541682A (ja) | 2022-11-21 | 2025-12-23 | ツリーライン バイオサイエンシズ インコーポレイテッド | スピロ環式ジヒドロピランピリミジンＫＲａｓ阻害剤 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| TW202504599A (zh) | 2023-06-30 | 2025-02-01 | 美商必治妥美雅史谷比公司 | Kras抑制劑 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202515570A (zh) | 2023-08-17 | 2025-04-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ｋｒａｓ抑制劑 |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| AU2024344161A1 (en) | 2023-09-21 | 2026-03-26 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyridine kras inhibitors |
| AU2024354737A1 (en) | 2023-10-06 | 2026-04-16 | Amgen Inc. | Combination therapy for cancer treatment |
| AU2024358992A1 (en) | 2023-10-09 | 2026-04-23 | Incyte Corporation | Combination comprising a kras g12d inhibitor and an egfr inhibitor for use in the treatment of cancer |
| WO2025080593A1 (en) | 2023-10-09 | 2025-04-17 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090333A1 (en) | 2024-10-23 | 2026-04-30 | Incyte Corporation | Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer |
| WO2026090323A1 (en) | 2024-10-23 | 2026-04-30 | Incyte Corporation | Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor and its use in the treatment of cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10822312B2 (en) * | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| PH12019500056B1 (en) | 2016-07-12 | 2024-01-31 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| BR112019015075A2 (pt) | 2017-01-23 | 2020-03-10 | Revolution Medicines, Inc. | Compostos bicíclicos como inibidores de shp2 alostéricos |
| SG11201906412SA (en) | 2017-01-23 | 2019-08-27 | Revolution Medicines Inc | Pyridine compounds as allosteric shp2 inhibitors |
| ES2905676T3 (es) | 2017-05-22 | 2022-04-11 | Amgen Inc | Inhibidores de KRAS G12C y métodos para su uso |
| CN111051306B (zh) | 2017-09-08 | 2023-01-03 | 美国安进公司 | Kras g12c的抑制剂及其使用方法 |
| SG11202002941WA (en) | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| CA3123227A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| PE20211475A1 (es) | 2018-12-20 | 2021-08-05 | Amgen Inc | Inhibidores de kif18a |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| MX2021007157A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
| EP4203952A4 (en) * | 2020-08-28 | 2024-12-11 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| JP2024506329A (ja) * | 2021-02-09 | 2024-02-13 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| JP2024508755A (ja) * | 2021-02-16 | 2024-02-28 | セラス， インコーポレイテッド | Ｋｒａｓを阻害するための組成物及び方法 |
| WO2022184178A1 (en) * | 2021-03-05 | 2022-09-09 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| MX2023014786A (es) * | 2021-06-10 | 2024-01-11 | Redx Pharma Plc | Derivados quinazolina utiles como inhibidores de ras. |
-
2023
- 2023-02-15 MX MX2024010045A patent/MX2024010045A/es unknown
- 2023-02-15 CN CN202380032897.3A patent/CN118974055A/zh active Pending
- 2023-02-15 US US18/838,954 patent/US20250163064A1/en active Pending
- 2023-02-15 WO PCT/US2023/062687 patent/WO2023159086A1/en not_active Ceased
- 2023-02-15 AU AU2023222076A patent/AU2023222076A1/en active Pending
- 2023-02-15 EP EP23711641.3A patent/EP4479401A1/en active Pending
- 2023-02-15 JP JP2024547690A patent/JP2025508702A/ja active Pending
- 2023-02-15 CA CA3251001A patent/CA3251001A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508703A5 (enExample) | ||
| JP2024532735A5 (enExample) | ||
| CA2052884C (en) | Angiotensin 11 antagonists in the treatment of hyperuricemia | |
| JP2023512038A5 (enExample) | ||
| CN103402519B (zh) | 肿瘤治疗剂 | |
| EP3268490B1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| JP2007535520A5 (enExample) | ||
| JP2018531983A (ja) | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 | |
| JP2016538313A5 (enExample) | ||
| JP2021501145A5 (enExample) | ||
| JP2017528487A5 (enExample) | ||
| KR20180102544A (ko) | Trk 억제제-내성 암에서의 점 돌연변이 및 이의 관련 방법 | |
| JP2019511526A5 (enExample) | ||
| TW201617337A (zh) | 經苯甲基取代之吲唑 | |
| JP2024544625A (ja) | がんを処置するためのｃｄｋ２阻害剤およびｃｄｋ４阻害剤を含む方法および投薬レジメン | |
| WO2018206547A1 (en) | Combination of bub1 and atr inhibitors | |
| JP2015514101A5 (enExample) | ||
| JP7662528B2 (ja) | 複素環式タンパク質キナーゼ阻害剤を含む製剤 | |
| JP2025519119A (ja) | Ｍｅｋ阻害剤及びその使用 | |
| ES2685974T3 (es) | Derivados de cefalosporina para tratar el cáncer | |
| CN101484443A (zh) | 放射线治疗增强剂 | |
| WO2019180141A1 (en) | Combinations of rogaratinib | |
| EP2425830A1 (en) | Synergistic drug combination for the treatment of cancer | |
| CA2577664A1 (en) | Novel heterocycles | |
| US20210369724A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |